Tech Company M&A Transactions
AkaRx Acquisition
AkaRx, based in Paramus, was purchased by Eisai of North America. The companies indicated that total deal value was $255 million.
Transaction Overview
Company Name
Acquired By
Announced On
1/8/2010
Transaction Type
M&A
Amount
$255,000,000
M&A Terms
Eisai Co. Ltd. has acquired AkaRx Inc., a Paramus, N.J.-based drug company focused on thrombocytopenia, for $255 million.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
South 61 Paramus Rd.
Paramus, NJ 07652
USA
Paramus, NJ 07652
USA
Phone
Website
Email Address
Not Recorded
Overview
AkaRx, Inc. is a biopharmaceutical company headquartered in Paramus, New Jersey, and dedicated to the development of novel therapeutic treatments that address unmet medical needs and provide significant benefits over currently available therapies.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Robert Desjardins
Chief Operating Officer
Donna Tempel
VP - Operations
Steven Silbert
VP - Regulatory Affairs
Rudolph Lucek
Browse more venture capital transactions:
Prev: 1/8/2010: Reframe It venture capital transaction
Next: 1/8/2010: Hootsuite venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to record every notable VC transaction. VC investment data records reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs